​

Lite Strategy Stock (NASDAQ:LITS)


OwnershipFinancialsChart

Previous Close

$0.86

52W Range

$0.69 - $2.00

50D Avg

$1.16

200D Avg

$1.07

Market Cap

$23.75M

Avg Vol (3M)

$525.72K

Beta

0.04

Div Yield

-

LITS Company Profile


Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Dec 18, 2003

Website

LITS Performance


LITS Financial Summary


Jun 25Jun 24Jun 23
Revenue-$65.30M$48.82M
Operating Income$-17.45M$14.54M$-36.76M
Net Income$-15.95M$17.78M$-31.84M
EBITDA$-17.09M$25.82M$-36.38M
Basic EPS$-2.39$2.67$-4.78
Diluted EPS$-2.39$2.67$-4.78

Fiscal year ends in Jun 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 23Sep 26, 23 | 5:00 PM
Q4 22Sep 08, 22 | 5:00 PM
Q4 21Sep 02, 21 | 5:00 PM

Peer Comparison


TickerCompany
HOWLWerewolf Therapeutics, Inc.
NTRBNutriband Inc.
TCRXTScan Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ACETAdicet Bio, Inc.
XBITXBiotech Inc.
PMVPPMV Pharmaceuticals, Inc.
IMUXImmunic, Inc.
IOBTIO Biotech, Inc.
RLMDRelmada Therapeutics, Inc.